Taken together, our data suggest that treatment with oxytetracycline could suppress CD133+ HCC population and LCSC properties via destabilization of CD133 in CD133+ HCC cells, thereby promoting the therapeutic efficacy of oxytetracycline in human liver carcinomas. Here, PROM1 is linked to hepatocellular carcinoma.